Applied Molecular Transport doses first patient in Phase 2 ulcerative colitis trial

Applied Molecular Transport (NASDAQ:AMTI) initiated its Phase 2a trial evaluating AMT-101 for the treatment of ulcerative colitis.

The trial will enrol some 100 patients with moderate-to-severely active ulcerative colitis who will receive either oral AMT-101 or placebo for 12 weeks of treatment. The study’s primary endpoint is to assess the efficacy of repeat oral doses of AMT-101, versus placebo, in reducing components of the Mayo score, a disease activity index for ulcerative colitis.        

“In our successful Phase 1b study, we demonstrated that oral doses of AMT-101 were safe and improved objective disease markers in patients with ulcerative colitis after just two weeks of treatment,” Dr. Bittoo Kanwar, the company’s CMO, said in a statement. 

“As an oral, gut-selective immunomodulatory biologic therapy, AMT-101 could significantly improve the lives of patients with ulcerative colitis,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.